ECSP024393A - SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH - Google Patents
SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTHInfo
- Publication number
- ECSP024393A ECSP024393A EC2002004393A ECSP024393A ECSP024393A EC SP024393 A ECSP024393 A EC SP024393A EC 2002004393 A EC2002004393 A EC 2002004393A EC SP024393 A ECSP024393 A EC SP024393A EC SP024393 A ECSP024393 A EC SP024393A
- Authority
- EC
- Ecuador
- Prior art keywords
- treatment
- compounds
- formula
- cellular growth
- normal cellular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a compuestos de fórmula I: Y a sales solvatos o profármacos farmacéuticamente aceptable de los mismos, en los cuales R1, R3, R4, R5, R11, m y p son tales como se han definido en la presente memoria. La invención se refiere también a métodos para tratar el crecimiento celular anormal en animales mamíferos administrando los compuestos de fórmula I, y a composiciones farmacéuticas para tratar los trastornos, que contienen los compuestos de la fórmula I. La invención se refiere también a métodos para preparar los compuestos de fórmula I.The invention relates to compounds of formula I: And to pharmaceutically acceptable solvate salts or prodrugs thereof, in which R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods for treating abnormal cell growth in mammalian animals by administering the compounds of formula I, and pharmaceutical compositions for treating disorders, which contain the compounds of formula I. The invention also relates to methods for preparing the compounds of formula I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21313600P | 2000-06-22 | 2000-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP024393A true ECSP024393A (en) | 2003-02-06 |
Family
ID=22793862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2002004393A ECSP024393A (en) | 2000-06-22 | 2002-12-13 | SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH |
Country Status (43)
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
IL142257A0 (en) * | 1998-10-01 | 2002-03-10 | Astrazeneca Ab | Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases |
CA2413424C (en) * | 2000-06-22 | 2007-10-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
DE60237145D1 (en) * | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | quinazoline derivatives |
US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
ATE377009T1 (en) * | 2001-11-30 | 2007-11-15 | Osi Pharm Inc | METHOD FOR PRODUCING SUBSTITUTED BICYCLIC DERIVATIVES FOR TREATING ABNORMAL CELL GROWTH |
GEP20063872B (en) * | 2001-12-12 | 2006-07-10 | Pfizer Prod Inc | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production |
CN1602195A (en) * | 2001-12-12 | 2005-03-30 | 辉瑞产品公司 | Quinazoline derivatives for the treatment of abnormal cell growth |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP1521747B1 (en) * | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
WO2004046101A2 (en) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
CA2510323A1 (en) * | 2002-12-18 | 2004-07-01 | Pfizer Products Inc. | 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
AU2003283743A1 (en) * | 2002-12-19 | 2004-07-14 | Pfizer Products Inc. | Complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
MXPA05008810A (en) * | 2003-04-09 | 2005-10-18 | Pfizer Prod Inc | Processes for the preparation of n-((((pyridinyloxy) -phenylamino) quinazolinyl)- allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates. |
EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
AU2004257362A1 (en) * | 2003-07-15 | 2005-01-27 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
CN102432552B (en) * | 2003-08-14 | 2016-01-20 | 阿雷生物药品公司 | As the quinazoline analogs of receptor tyrosine kinase inhibitors |
KR20060037447A (en) * | 2003-08-18 | 2006-05-03 | 화이자 프로덕츠 인크. | Dosing schedule for erbb2 anticancer agents |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
BRPI0416190A (en) * | 2003-11-06 | 2007-01-23 | Pfizer Prod Inc | selective erbb2 inhibitor / anti erbb antibody combinations in cancer treatment |
EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
CA2573821A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
WO2006025490A1 (en) * | 2004-09-01 | 2006-03-09 | Mitsubishi Pharma Corporation | Molecular chaperone function regulator |
KR100735639B1 (en) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof |
WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
BRPI0608096A2 (en) | 2005-04-26 | 2009-11-10 | Pfizer | p-cadherin antibodies |
CA2610491A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Bicyclic derivatives for the treatment of abnormal cell growth |
US20080194596A1 (en) * | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
UA94060C2 (en) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Monoclonal antibodies that specifically binds alk-1 |
CA2755268C (en) * | 2005-11-15 | 2013-12-31 | Array Biopharma, Inc. | Erbb inhibitors |
GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
EA200802058A1 (en) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS |
WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
SG174774A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
KR20090077914A (en) * | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | Multi-functional small molecules as anti-proliferative agents |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
RU2009126576A (en) | 2006-12-12 | 2011-01-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | CONDENSED HETEROCYCLIC COMPOUND |
AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
JP5926487B2 (en) | 2007-04-13 | 2016-05-25 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Method for treating cancer resistant to ErbB therapy |
ME01461B (en) | 2008-02-07 | 2014-04-20 | Boehringer Ingelheim Int | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
PE20091580A1 (en) | 2008-03-12 | 2009-11-05 | Takeda Pharmaceutical | FUSED HETEROCYCLIC COMPOUND |
US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
EP2313397B1 (en) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method |
KR20200137052A (en) | 2009-01-16 | 2020-12-08 | 엑셀리시스, 인코포레이티드 | Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
EP2630134B9 (en) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
WO2013042006A1 (en) | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
CN102872018B (en) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | Tyrosine kinase irreversible inhibitor and preparation method and applications thereof |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
PT3137460T (en) | 2014-04-30 | 2019-12-30 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
KR101589632B1 (en) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 6-Benzyloxyquinazolin-7-ylurea derivatives with an anticancer activity |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
ES2882255T3 (en) | 2015-07-01 | 2021-12-01 | California Inst Of Techn | Delivery systems based on cationic mucic acid polymers |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
JP6791979B2 (en) | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | Nitrogen-containing heterocyclic compounds, production methods, intermediates, compositions and applications |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
EP4360713A2 (en) | 2018-09-18 | 2024-05-01 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
TW202345816A (en) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Nitrogen-containing heterocyclic compounds, their preparation methods and their medical use |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW321649B (en) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US7262201B1 (en) | 1998-10-08 | 2007-08-28 | Astrazeneca Ab | Quinazoline derivatives |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (en) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
CA2413424C (en) * | 2000-06-22 | 2007-10-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
-
2001
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 EA EA200201277A patent/EA005525B1/en not_active IP Right Cessation
- 2001-06-14 IL IL15298501A patent/IL152985A0/en unknown
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/en unknown
- 2001-06-14 DK DK01938484T patent/DK1292591T3/en active
- 2001-06-14 UA UA20021210405A patent/UA73990C2/en unknown
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/en not_active IP Right Cessation
- 2001-06-14 CN CN01811470A patent/CN1437594A/en active Pending
- 2001-06-14 DE DE60108754T patent/DE60108754T2/en not_active Expired - Lifetime
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/en not_active Expired - Fee Related
- 2001-06-14 PT PT01938484T patent/PT1292591E/en unknown
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/en unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/en not_active Expired - Lifetime
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/en not_active Expired - Fee Related
- 2001-06-14 YU YU95102A patent/YU95102A/en unknown
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en active Application Filing
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 PL PL01359557A patent/PL359557A1/en not_active Application Discontinuation
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/en active IP Right Grant
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/en active Pending
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/en unknown
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 AT AT01938484T patent/ATE288431T1/en not_active IP Right Cessation
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/en not_active IP Right Cessation
- 2001-06-14 EE EEP200200710A patent/EE200200710A/en unknown
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 NZ NZ522568A patent/NZ522568A/en unknown
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 AR ARP010102936A patent/AR032353A1/en unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/en not_active Application Discontinuation
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/en unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/en unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/en not_active Application Discontinuation
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/en unknown
- 2002-11-14 IS IS6616A patent/IS6616A/en unknown
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/en unknown
- 2002-12-13 HR HR20021005A patent/HRP20021005A2/en not_active Application Discontinuation
- 2002-12-16 MA MA26954A patent/MA26914A1/en unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166L/en unknown
-
2005
- 2005-03-11 HK HK05102099A patent/HK1069576A1/en not_active IP Right Cessation
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP024393A (en) | SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH | |
ECSP055633A (en) | NEW BENZOIMIDAZOLUTILES DERIVATIVES AS ANTIPROLIFERATIVE ANGENTS | |
UY28135A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
PA8487601A1 (en) | USEFUL SUBSTITUTED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER | |
AR046297A1 (en) | DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS | |
CU23132A3 (en) | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | |
PA8490601A1 (en) | QUINOLIN-2-ONA DERIVATIVES SUBSTITUTED WITH HETEROARILO USEFUL AS ANTICANCERIGEN AGENTS. | |
AR054347A1 (en) | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
UY28132A1 (en) | PIRROLOPIRIMIDINE DERIVATIVES | |
UY28357A1 (en) | DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND ITS USES | |
DOP2002000519A (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
PA8592801A1 (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
PA8474401A1 (en) | 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN | |
UY26785A1 (en) | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
UY27557A1 (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH. | |
BRPI0515835A (en) | tetraline and indane derivatives and their uses | |
DOP2003000786A (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH. | |
UY28131A1 (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
ECSP993260A (en) | USEFUL SUBSTITUTE BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER | |
ECSP099644A (en) | DERIVATIVES OF QUINOLINA, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THE USE OF SUCH IN THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISEASES | |
ECSP993117A (en) | DERIVATIVES OF QUINOLIN -2 - ONA USEFUL AS AGENTS AGAINST CANCER | |
ECSP003347A (en) | QUINOLIN DERIVATIVES - 2- ONA SUBSTITUTED WITH HETEROARILO USEFUL AS ANTI-BANERIGINAL AGENTS | |
CR6833A (en) | SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
GT200100120A (en) | REPLACED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
ECSP003793A (en) | NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS |